About Autolus
Autolus is a company based in London (United Kingdom) founded in 2015. Autolus has raised $181.37 million across 5 funding rounds from investors including BioNTech, Blackstone and Syncona. The company has 647 employees as of December 31, 2024. Autolus operates in a competitive market with competitors including Moderna, Senti Biosciences, Horizon Therapeutics, Forge Biologics and argenx, among others.
- Headquarter London, United Kingdom
- Employees 647 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Autolus Therapeutics Plc Sponsored Adr
-
Annual Revenue
$10.12 M (USD)496.25as on Dec 31, 2024
-
Net Profit
-$220.75 M (USD)-5.94as on Dec 31, 2024
-
EBITDA
-$213.46 M (USD)-13.27as on Dec 31, 2024
-
Total Equity Funding
$181.37 M (USD)
in 5 rounds
-
Latest Funding Round
$200 M (USD), Post-IPO
Feb 08, 2024
-
Investors
BioNTech
& 5 more
-
Employee Count
647
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Autolus
Autolus is a publicly listed company on the NASDAQ with ticker symbol AUTL in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
People of Autolus
Unlock access to complete
Leadership Team
31 people
Software Development Team
27 people
Senior Team
22 people
Product Management Team
12 people
Finance and Accounting
7 people
Operations Team
6 people
Research Team
5 people
Human Resources and Administration
5 people
Unlock access to complete
Funding Insights of Autolus
Autolus has successfully raised a total of $181.37M across 5 strategic funding rounds. The most recent funding activity was a Post-IPO round of $200 million completed in February 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Autolus
Autolus has secured backing from 6 investors, including institutional and venture fund investors. Prominent investors backing the company include BioNTech, Blackstone and Syncona.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Diversified investment management is provided across multiple asset classes.
|
Locked | Locked | Locked | |
|
PE firm investing in the US
|
Locked | Locked | Locked | |
|
Healthcare investments are managed via private equity by Syncona.
|
Locked | Locked | Locked |
Investor details for Autolus
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Autolus
Investment portfolio details for Autolus
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Autolus
Detailed financials for Autolus
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Autolus Comparisons
Peer comparison for Autolus
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Autolus
Autolus operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Senti Biosciences, Horizon Therapeutics, Forge Biologics and argenx, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Cell-based therapies for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Developer of drugs for treating rare and autoimmune diseases
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases are developed to treat patients.
|
|
| Locked | Locked | Locked |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment.
|
|
| Locked | Locked | Locked |
Provider of cell therapies to treat cancer and hematologic conditions
|
Detailed competitors of Autolus
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Autolus
Complete news archive for Autolus
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Autolus
Autolus was founded in 2015.
Autolus is headquartered in London, United Kingdom. It is registered at London, England, United Kingdom.
Christian Martin Itin is the current CEO of Autolus.
Autolus is a funded company, having raised a total of $181.37M across 5 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Autolus is 647.
Annual revenue of Autolus is $10.12M as on Dec 31, 2024.
Autolus was founded in 2015 in London, United Kingdom, within the biotechnology sector. Engineered T-cell therapies are developed and commercialized by the company, targeting hematological and solid tumors. A pipeline of CAR T-cell products is advanced using proprietary targets, constructs, and technologies. Emphasis is placed on immunotherapy applications for cancer and auto-immune conditions.
Autolus's top competitors include Moderna, argenx and Forge Biologics.
Yes, Autolus is publicly traded on NASDAQ under the ticker symbol AUTL.
Autolus has 6 investors. Key investors include BioNTech, Blackstone, Syncona, Arix Bioscience, and Woodford Investment Management.
The ticker symbol of Autolus is AUTL on NASDAQ.